HSPA1A (Heat Shock Protein Family A (Hsp70) Member 1A)

These findings uncover a previously unrecognized EP300-H2BK5ac-HSPA1A regulatory pathway that links environmental exposure to biomechanical and epigenetic remodeling in lung cancer. Targeting this axis may offer new strategies to mitigate B(a)P-driven metastasis.

PAL is suggested as a promising new therapeutic agent for malignant melanoma.

These findings indicated that DMC functions as an effective chemosensitizer, elevating TMZ efficacy. Combining DMC with DNA repair inhibitors may represent a promising therapeutic strategy to overcome resistance and improve IDH-wildtype grade diffuse glioma treatment outcomes.

Multimodal model achieved satisfactory performance on classifying tumor invasiveness, and provided effective strategy for high-invasiveness tumor to reduce LTP occurrence.

These findings highlight the regulatory role of RBPs in ICI-induced colitis and identify cell-type-specific alterations that may drive disease progression. Importantly, we pinpoint immune checkpoint-related RBPs as potential therapeutic targets, offering new strategies to manage this clinically significant irAE.

Our findings identify PI4KIII alpha activity as a key regulator of PI(4)P accumulation and subsequent HSPA1A recruitment to the PM in stressed and cancer cells. This lipid-mediated response offers new insights into stress adaptation and potentially modifiable pathways for therapeutic interventions to control HSPA1A function in cancer.

Our study provides a comprehensive single-cell transcriptomic atlas of thyroid cancer, offering profound insights into tumor heterogeneity, the functional roles of key niche cells, and potential biomarkers for anticancer therapy. These findings not only enhance our understanding of thyroid cancer biology but also pave the way for the development of novel therapeutic strategies targeting the TME.

Furthermore, in vitro experiments demonstrated that knockdown of two key genes, ABHD4 and YJEFN3, significantly suppressed CRC cell proliferation, migration, and invasion, supporting their potential oncogenic roles. This mitochondrial lipid metabolism-based risk model represents a promising prognostic biomarker, offering potential guidance for personalized therapeutic strategies in CRC management.

The findings of this study have significant clinical implications, suggesting that our nine-gene prognostic model could be integrated into routine clinical practice to enhance patient stratification and inform treatment decisions for COAD. Future research should focus on prospective validation and exploration of therapeutic targets within the identified genes.

CIC-key-CD8 T cells are pivotal in modulating the tumour microenvironment and can significantly impact the clinical outcome of colon cancer. Their high infiltration rate correlates with poor outcomes and immunotherapy resistance. Targeting these cells may improve therapeutic strategies for cancer immune checkpoint inhibitor treatments.

This study demonstrated that the YBX1-modulated IGFL2-AS1/HSPA1A/RAP1 axis is aberrantly activated in lung cancer cells and is associated with unfavorable prognosis, highlighting its potential as a novel therapeutic target in clinical settings.

This study demonstrates that BD exerts potent antitumor effects against HCC by inhibiting proliferation, inducing apoptosis, and suppressing migration, primarily through disruption of the Hsp70/STAT3 signaling axis. With its favorable safety profile, BD represents a promising candidate for further development as a therapeutic agent in HCC.